How Many Doses Vial TB-4? (Reconstitution Guide)

How Many Doses Vial TB-4? (Reconstitution Guide)

A standard 5mg TB-4 vial yields between 10 and 20 research doses depending on your reconstitution volume and target dose per administration. Most research protocols use 500mcg (0.5mg) or 250mcg (0.25mg) per injection—meaning one 5mg vial delivers 10 doses at the higher concentration or 20 doses at the lower concentration when properly reconstituted with bacteriostatic water. The dose count isn't printed on the vial because it's variable—you determine it through your reconstitution math.

How many doses are in a 5mg vial of TB-4?

A 5mg vial of TB-4 (Thymosin Beta-4) contains 10 doses at 500mcg each or 20 doses at 250mcg each when reconstituted with 2mL of bacteriostatic water. The number of doses depends on the concentration you create during reconstitution and the volume you draw per injection—most research protocols use 0.2mL (500mcg) or 0.1mL (250mcg) per dose.

The confusion around how many doses vial TB-4 contains stems from the fact that lyophilised peptides arrive as powder—not pre-measured liquid doses. You're not buying a fixed number of injections; you're buying a fixed mass of peptide (typically 5mg) that you dilute to your preferred concentration. A 10mg vial doubles your dose count: 20 injections at 500mcg or 40 injections at 250mcg. This article covers the exact reconstitution math, why concentration matters for dosing accuracy, and what mistakes compromise peptide stability before the first injection.

Understanding TB-4 Vial Sizes and Peptide Mass

Thymosin Beta-4 vials are sold by peptide mass—not by volume or dose count. The most common format at Real Peptides and across research suppliers is the 5mg vial, though 2mg and 10mg formats exist. The number on the vial (5mg, 10mg) represents the total mass of lyophilised TB-4 powder inside—not the number of milligrams per dose or per milliliter. That distinction matters because dose count is derived from peptide mass divided by target dose per injection.

A 5mg vial contains 5,000 micrograms (mcg) of TB-4. If your research protocol calls for 500mcg per injection, you can extract 10 doses from that vial (5,000mcg ÷ 500mcg = 10 doses). If your protocol uses 250mcg per injection—a lower maintenance dose common in tissue repair studies—that same 5mg vial yields 20 doses (5,000mcg ÷ 250mcg = 20 doses). The peptide mass is fixed; the dose count is variable.

Reconstitution volume determines concentration—the ratio of peptide mass to liquid volume. Most researchers reconstitute 5mg vials with 2mL of bacteriostatic water, creating a 2.5mg/mL solution. At this concentration, each 0.1mL contains 250mcg of TB-4, and each 0.2mL contains 500mcg. Drawing 0.2mL per injection yields 10 doses per vial; drawing 0.1mL yields 20 doses. The math is straightforward, but errors occur when researchers reconstitute inconsistently or miscalculate draw volume on insulin syringes.

The half-life of TB-4 is approximately 2–2.5 hours in vivo, which is why research protocols typically administer it twice weekly or daily during loading phases. The short half-life doesn't affect vial shelf life—once reconstituted with bacteriostatic water and refrigerated at 2–8°C, TB-4 remains stable for 28 days. Unreconstituted lyophilised powder stored at −20°C maintains potency for 12–24 months. Understanding these stability windows is critical because a vial that yields 20 theoretical doses is worthless if half those doses degrade before administration.

Reconstitution Math: How Concentration Determines Dose Count

The number of doses you extract from a TB-4 vial depends entirely on the concentration you create during reconstitution. Concentration is expressed as milligrams of peptide per milliliter of solution (mg/mL). To calculate it, divide peptide mass by reconstitution volume. For a 5mg vial reconstituted with 2mL of bacteriostatic water: 5mg ÷ 2mL = 2.5mg/mL. Every milliliter of that solution contains 2.5mg (2,500mcg) of TB-4.

Once you know concentration, calculating dose volume is simple. If your target dose is 500mcg and your concentration is 2.5mg/mL (2,500mcg/mL), divide target dose by concentration: 500mcg ÷ 2,500mcg/mL = 0.2mL per injection. If your target dose is 250mcg, the calculation is 250mcg ÷ 2,500mcg/mL = 0.1mL per injection. The total volume in the vial (2mL) divided by dose volume (0.2mL or 0.1mL) gives you dose count: 2mL ÷ 0.2mL = 10 doses, or 2mL ÷ 0.1mL = 20 doses.

Some researchers prefer higher concentrations to reduce injection volume. Reconstituting a 5mg vial with 1mL instead of 2mL creates a 5mg/mL solution—twice as concentrated. At 5mg/mL, a 500mcg dose requires only 0.1mL instead of 0.2mL. This yields the same 10 doses per vial but reduces the volume per injection. Smaller injection volumes are easier to measure accurately with insulin syringes and reduce the risk of injection site discomfort in animal models.

The most common error is forgetting to account for dead space—the peptide solution that remains in the vial after the final draw. Standard glass vials retain approximately 0.05–0.1mL of solution that's physically inaccessible with a standard needle. If you reconstitute with 2mL and calculate 10 doses at 0.2mL each, you'll extract 9 full doses and one partial dose—not 10 perfect ones. This is why experienced researchers slightly overestimate reconstitution volume or accept that the final dose may be underdosed. At Real Peptides, every vial undergoes small-batch synthesis with exact amino-acid sequencing to guarantee the labeled peptide mass is accurate—eliminating underfilling as a variable.

Standard TB-4 Dosing Protocols and Vial Yield

Research protocols for Thymosin Beta-4 typically fall into two categories: loading phases and maintenance phases. Loading phases use higher doses (500mcg to 2mg) administered twice weekly or daily for 4–6 weeks to saturate tissue receptors and initiate repair mechanisms. Maintenance phases use lower doses (250mcg to 500mcg) administered once or twice weekly to sustain tissue remodeling and anti-inflammatory effects. The phase determines dose count per vial.

A common loading protocol is 500mcg twice weekly for four weeks—eight total injections. A single 5mg vial reconstituted at 2.5mg/mL yields 10 doses at 500mcg, covering the four-week loading phase with two doses remaining. For maintenance, 250mcg twice weekly extends one 5mg vial across 10 weeks (20 doses ÷ 2 doses per week = 10 weeks). Researchers running longer studies often purchase 10mg vials to reduce reconstitution frequency—a 10mg vial at 2.5mg/mL concentration delivers 40 doses at 250mcg or 20 doses at 500mcg.

Some advanced protocols use higher doses—up to 2mg per injection during acute injury phases. A 2mg dose from a 5mg vial reconstituted with 2mL requires 0.8mL per injection, yielding only 2.5 doses per vial. This is where vial size selection matters: researchers administering high doses should purchase 10mg vials to avoid frequent reconstitution, which increases contamination risk. Every time you puncture a vial septum with a needle, you introduce potential bacterial contamination—even with bacteriostatic water, which inhibits bacterial growth but doesn't sterilize.

Half-life considerations also affect dosing schedules. TB-4's 2–2.5 hour half-life means plasma levels peak within hours and decline rapidly. Despite this, tissue-level effects persist much longer—TB-4 upregulates actin polymerization and VEGF (vascular endothelial growth factor) expression for days after a single administration. This is why twice-weekly dosing remains effective even though the peptide itself clears quickly. The protocol isn't maintaining constant plasma levels; it's triggering repeated signaling cascades that outlast the peptide's presence.

Our experience working with research teams indicates that dose count per vial becomes critical in long-term studies—budgeting peptide supply incorrectly midway through a 12-week protocol compromises continuity. Calculating total doses required (injections per week × study duration in weeks) before ordering ensures you purchase the correct vial size and quantity upfront.

How Many Doses Vial TB-4: Dosing Comparison

The table below compares dose yields across standard vial sizes and reconstitution scenarios, showing how peptide mass, reconstitution volume, and target dose interact to determine total injections per vial.

Key Takeaways

• A 5mg TB-4 vial yields 10 doses at 500mcg each or 20 doses at 250mcg each when reconstituted with 2mL of bacteriostatic water.
• Dose count is determined by dividing total peptide mass by target dose per injection—vial labels show mass, not pre-measured doses.
• Reconstitution concentration (mg/mL) dictates injection volume—higher concentrations reduce volume per dose but deliver the same peptide mass.
• Once reconstituted, TB-4 remains stable for 28 days when refrigerated at 2–8°C; unreconstituted powder lasts 12–24 months at −20°C.
• Standard insulin syringes measure in 0.01mL increments—calculating dose volume accurately is critical to avoiding under- or overdosing.
• Dead space in vials retains 0.05–0.1mL of solution—expect one partial dose at the end of each vial regardless of calculated yield.

What If: TB-4 Dosing Scenarios

What If I Accidentally Reconstitute with the Wrong Volume?

Recalculate your concentration immediately using actual volume added, then adjust draw volume accordingly. If you added 3mL instead of 2mL to a 5mg vial, your concentration is 5mg ÷ 3mL = 1.67mg/mL (1,670mcg/mL). For a 500mcg dose, draw 0.3mL instead of 0.2mL (500mcg ÷ 1,670mcg/mL = 0.3mL). The peptide mass hasn't changed—only the concentration. The vial still contains 5mg total; you'll just draw larger volumes per dose. Label the vial with the corrected concentration to avoid confusion on subsequent draws.

What If I Run Out of Bacteriostatic Water Mid-Reconstitution?

Do not reconstitute with sterile water or saline as a substitute—both lack the benzyl alcohol preservative that inhibits bacterial growth during multi-dose use. Partially reconstituted peptide exposed to air and then stored is at high contamination risk. If you added less than the intended volume, calculate the new concentration and continue—underfilling slightly is safer than switching diluents. Order bacteriostatic water from reputable suppliers like Real Peptides before starting reconstitution to avoid mid-process shortages.

What If My Vial Yields Fewer Doses Than Calculated?

Dead space is the most common cause—standard vials retain 0.05–0.1mL that's inaccessible with a needle. If you calculated 10 doses at 0.2mL each (2mL total) but only extracted 9 full doses, 0.1–0.2mL remained trapped. This isn't a manufacturing defect; it's physics. Some researchers tilt the vial or use longer needles to access residual solution, but this increases contamination risk. Accept that the final dose will be slightly underdosed or calculate an extra 5% volume during reconstitution to compensate.

What If I Want to Change My Dose Mid-Study?

Recalculate draw volume based on existing concentration—you don't need to reconstitute a new vial. If your current concentration is 2.5mg/mL and you want to reduce from 500mcg (0.2mL) to 250mcg (0.1mL), simply draw half the volume per injection. The remaining solution in the vial is still usable for the new dose amount. This flexibility is why understanding concentration math matters—one vial can serve multiple dosing protocols without waste.

The Practical Truth About TB-4 Dose Count

Here's the honest answer: the number of doses per vial isn't fixed—it's a function of your math. If you reconstitute inconsistently or miscalculate draw volume, you'll either waste peptide by overdosing or compromise research outcomes by underdosing. The vial label tells you peptide mass; everything else is on you. Researchers who don't calculate concentration before the first draw are guessing—and guessing with precision compounds means unpredictable results.

The single most common error we see is assuming "one vial = one month" without doing the dose math. A 5mg vial lasts four weeks at 500mcg twice weekly (eight doses) but 10 weeks at 250mcg twice weekly (20 doses). The difference isn't trivial—miscalculating supply halfway through a study introduces a washout period that resets tissue-level effects. TB-4's mechanism depends on sustained signaling through repeated administration; even a one-week gap between vials can blunt the response.

Compounding this is the stability window. Once reconstituted, TB-4 is stable for 28 days refrigerated. If your dose count per vial is 20 and you're injecting once weekly, that vial covers 20 weeks—but the peptide degrades after four weeks. The solution isn't buying smaller vials (which increases per-dose cost); it's adjusting reconstitution volume or accepting that doses 5+ may have reduced potency. Advanced researchers reconstitute only half the powder at a time by adding 1mL, using it within 28 days, then reconstituting the second half—but this requires splitting powder accurately, which most labs can't do reliably.

Real Peptides addresses this through small-batch synthesis and exact sequencing—every 5mg vial contains 5mg of active TB-4, not 4.7mg or 5.3mg. When dose count calculations depend on labeled mass being accurate, even 5% variance compounds across a study. Precision at the source eliminates one variable researchers can't control downstream.

The truth most guides won't state plainly: if you don't understand reconstitution math, you shouldn't be handling research peptides. The stakes aren't just wasted money—they're compromised data integrity. A study dosed at 450mcg instead of 500mcg because of miscalculated draw volume isn't comparing apples to apples with published literature using standardized doses. TB-4 research is dose-dependent; the difference between 250mcg and 500mcg isn't splitting hairs—it's the difference between maintenance-level signaling and loading-phase tissue saturation. Dose accuracy matters, and dose accuracy starts with knowing how many doses your vial actually contains based on your reconstitution choices.

Your lab's credibility depends on documentation. Every reconstitution should be logged: vial size, bacteriostatic water volume added, calculated concentration, target dose, and calculated injection volume. When results are published, reviewers will ask about dosing precision. "We used TB-4" isn't sufficient; "We administered 500mcg per injection, reconstituted at 2.5mg/mL, drawn as 0.2mL using 1mL insulin syringes" is the standard. The dose count per vial is part of that documentation—it's how you prove consistent administration across the study timeline.

If you're running protocols that require high precision across multiple subjects, consider how vial size affects batch-to-batch consistency. Reconstituting one 10mg vial to dose 20 subjects once is more consistent than reconstituting two 5mg vials on different days—every reconstitution introduces measurement variance. Larger vials reduce variance but increase waste if the study ends early or a subject drops out. Balancing these tradeoffs is part of experimental design, and it starts with understanding that "how many doses vial TB-4" isn't a fixed number—it's a calculated output based on your protocol's requirements.

For researchers seeking reliable, research-grade TB-4 synthesized with exact amino-acid sequencing, Real Peptides delivers peptides you can count on—literally. Every vial ships with third-party purity verification, and our small-batch process ensures the labeled mass matches the actual peptide content. When your dose calculations depend on the vial containing exactly what it says, precision sourcing isn't optional—it's the foundation of reproducible research. Explore our TB 500 Thymosin Beta 4 and see how our commitment to quality extends across our full peptide collection.